Advertisement
Advertisement
U.S. markets open in 9 hours 1 minute
Advertisement
Advertisement
Advertisement
Advertisement

Cingulate Inc. (CING)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.4400+0.0200 (+1.41%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.4200
Open1.4550
Bid1.5000 x 800
Ask1.4500 x 900
Day's Range1.3799 - 1.4550
52 Week Range1.0400 - 5.1500
Volume19,657
Avg. Volume43,233
Market Cap16.286M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.1560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CING

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cingulate Inc.
    Daily – Vickers Top Insider Picks for 05/05/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

    CTx-2103 (buspirone) is the Third Candidate Using Cingulate’s Proprietary Precision Timed Release™ Drug Delivery Platform Technology for Once-daily Dosing Via Three Precise, Pre-defined Drug ReleasesKANSAS CITY, Kan., June 23, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today

  • GlobeNewswire

    UPDATE -- Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on June 23, 2022

    Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on June 23, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-minu

  • GlobeNewswire

    Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational

    KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, will present a company overview at the Diamond Equity Research 2022 Virtual Emerging Growth Invitational on Thursday, J

Advertisement
Advertisement